Hims & Hers Health, Inc. (HIMS) News
Filter HIMS News Items
HIMS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
HIMS News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest HIMS News From Around the Web
Below are the latest news stories about HIMS & HERS HEALTH INC that investors may wish to consider to help them evaluate HIMS as an investment opportunity.
3 US Growth Companies With Insider Ownership Up To 17%As the U.S. stock market experiences a Santa Claus Rally, with major indices like the Nasdaq Composite and S&P 500 posting gains, investors are keenly observing growth companies that demonstrate resilience and potential in this upbeat environment. In such a climate, stocks with high insider ownership can be particularly appealing as they often indicate confidence from those closest to the company's operations and future prospects. |
Should You Investigate Hims & Hers Health, Inc. (NYSE:HIMS) At US$28.15?Hims & Hers Health, Inc. ( NYSE:HIMS ), is not the largest company out there, but it led the NYSE gainers with a... |
IBD 50's Hims & Hers Tumbles After FDA Pulls Lilly's Weight-Loss Drug From Shortage ListHims stock skidded Thursday after the FDA determined Eli Lilly's tirzepatide — which sells as a weight-loss drug — is no longer in shortage. |
Eli Lily GLP-1 shortage ends, FDA says: Hims & Hers stock fallsHims & Hers Health (HIMS) shares tumble after the US Food and Drug Administration (FDA) announced that the shortage in Eli Lilly's (LLY) weight loss drug, Zepbound, has been resolved. The stock falls in anticipation of lower demand as the supply of GLP-1 weight-loss drugs improves. Julie Hyman and Josh Lipton examine the stock move and what investors need to know about the evolving GLP-1 market. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Naomi Buchanan. |
FDA finalizes decision to end Lilly's GLP-1 shortage, analysts predict Novo will be nextThe FDA decided the shortage for Eli Lilly's GLP-1 tirzepatide has finally come to an end. |
Tesla, crypto miners, Hims & Hers Health: Trending TickersThe Morning Brief team explores the latest stock recommendations from Wall Street analysts. Mizuho analysts have upgraded Tesla (TSLA) stock to Outperform from Neutral, citing potential policy shifts under the upcoming Trump administration. The firm suggests the repealing of EV tax credits by the incoming Trump administration could provide additional upside for the electric vehicle manufacturer. Piper Sandler has initiated coverage on several bitcoin (BTC-USD) miners and crypto firms, including MARA Holdings (MARA), Riot Platforms (RIOT), Hut 8 Mining (HUT), and Galaxy Digital (GLXY.TO) with an Overweight rating. Notably, Piper Sandler singled out MARA Holdings as the most compelling pure-play bitcoin mining stock. Additionally, Morgan Stanley initiated coverage on Hims & Hers Health (H... |
The Shape of America 2024: Hims & Hers Shares an In-Depth Look Into How Americans Feel About WeightSAN FRANCISCO, December 12, 2024--For most Americans, weight is more than just a number. It shapes our health, our mood, our confidence, our spending, and the decisions we make in our day to day lives. In fact, 75% of us think about our weight every single day, and 14% say it’s constantly on our minds. |
The Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion MarketAn age-old battle in pharmaceuticals could further rattle Eli Lilly stock and its potential $100 billion market in weight-loss drugs. |
3 US Stocks Estimated To Be Trading Up To 47.6% Below Intrinsic ValueAs the United States stock market reaches record highs with technology stocks leading the charge, investor optimism is fueled by expectations of pro-growth policies from the incoming administration. Amid this buoyant environment, identifying undervalued stocks can be a strategic approach for investors seeking opportunities that may not yet reflect their intrinsic value. |
Hims & Hers Named to Inc.’s 2024 Best in Business List in Health Products CategorySAN FRANCISCO, December 03, 2024--Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, is proud to announce its inclusion on the Inc. 2024 Best in Business list in the Health Products category. Inc.’s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made a profound impact on their industries and on society at large. |